Company: DMAAR
Filing Date: 2025-01-14
Form Type: POS AM
Source: 0001213900-25-003137
Chunk: 210

Company: Drugs Made In America Acquisition Corp.
Filing Date: 2025-01-14
Form: POS AM
Chunk 210
---
 aggregate of 666,667 founder shares held by the sponsor. The private units held by the sponsor, including the private units represented by the non -managingsponsor investors’ membership interests, are subject to a lock -upas described in ‘‘ Principal Shareholders— Restrictions on Transfers of Founder Shares and Private U nits’’; however, the non -managingsponsor investors will not be subject to transfer restrictions or a lock -upagreement on any public shares that they may purchase in this offering. As more fully discussed in “Management — Conflicts of Interest,” if any of our directors or officers becomes aware of a business combination opportunity that falls within the line of business of any entity to which he or she has then -currentfiduciary or contractual obligations, he or she may be required to present such business combination opportunity to such entity prior to presenting such business combination opportunity to us, subject to their fiduciary duties under Cayman Islands law. Our directors and officers currently have certain relevant fiduciary duties or contractual obligations that may take priority over their duties to us. We have entered into an administrative services agreement pursuant to which we have agreed to pay our sponsor or an affiliate $10,000 per month for office space, administrative and support services. Upon completion of our initial business combination or our liquidation, we will cease paying these monthly fees. Accordingly, in the event the consummation of our initial business combination takes 15 months, our sponsor or an affiliate will be paid a total of $150,000 ($10,000 per month) for office space, administrative and support services and will be entitled to be reimbursed for any out -of -pocketexpenses. Our audit committee will review and approve all payments that were made by us to our sponsor, directors, officers or our or any of their respective affiliates, which may include reimbursement of any out -of -pocketexpenses incurred in connection with activities on our behalf such as identifying potential target businesses and performing due diligence on suitable business combinations. There is no cap or ceiling on the reimbursement of out -of -pocketexpenses incurred by such persons in connection with activities on our behalf. Our sponsor has agreed to loan us up to $1,850,000 under an unsecured promissory note to be used for a portion of the expenses of this offering and to finance transaction costs in connection with an intended initial business combination. As of September30, 2024, we have borrowed $552,015 under such promissory note.